Kazuyuki Shimada1, Pier L. Zinzani2, Akihiro Tomita1, Kenichi Ishizawa3, Shinichiro Okamoto4, Itaru Matsumura5, Yoshinobu Maeda6, Koji Kato7, Akira Wakana8, Eunhee Kim9, Mohammed Farooqui9, Akash Nahar9, Takashi Shimamoto8, Yasuhiro Koh8, Craig H. Moskowitz10, Takanori Teshima11 (1.Nagoya University, Nagoya, Japan, 2.Institute of Hematology, University of Bologna, Bologna, Italian Republic, 3.Yamagata University, Yamagata, Japan, 4.Keio University, Tokyo, Japan, 5.Kindai University, Osaka, Japan, 6.Okayama University, Okayama, Japan, 7.Kyushu University, Fukuoka, Japan, 8.MSD K.K., Tokyo, Japan, 9.Merck & Co., Inc., Kenilworth, NJ, United States of America, 10.University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, United States of America, 11.Hokkaido University Hospital, Hokkaido, Japan)
Session information
Oral Session
Oral Session 3-7C Hodgkin Lymphoma
Sun. Oct 13, 2019 2:30 PM - 3:30 PM No.7 (Tokyo International Forum, 5F Hall D5)
Chair: Kazuhito Yamamoto (Aichi Cancer Center, Department of Hematology and Cell Therapy)
[OS3-7C-2] Efficacy of once-per-cycle pegfilgrastim with Hodgkin's lymphoma treated by A+AVD therapy
Yuki Osada1, Akihiko Nishijima1, Atsushi Hamamura1, Kensuke Narukawa1, Hina Takano2, Gaku Oshikawa1 (1.Department of Hematology, Japanese Red Cross Musashino Hospital, Tokyo, Japan, 2.Department of Transfusion, Japanese Red Cross Musashino Hospital, Tokyo, Japan)
Mototaka Hattori1, Yukiko Komeno1, Akiko Kobayashi3, Masami Ozu1, Keiko Abe2, Tomiko Ryu1 (1.Hematology, JCHO Tokyo Yamate Medical Center, Tokyo, Japan, 2.Pathology, JCHO Tokyo Yamate Medical Center, Tokyo, Japan, 3.Rheumatology, Tokyo Women's Medical University, Tokyo, Japan)
Yuka Ishii, Shinya Fujita, Jun Ichikawa, Ryo Saito, Akiko Konishi, Hideaki Yoshimura, Masaaki Hotta, Takahisa Nakanishi, Aya Nakaya, Atsushi Satake, Michihiko Miyaji, Yoshiko Azuma, Yukie Tsubokura, Tomoki Ito, Kazuyoshi Ishii, Shosaku Nomura (First Department of Internal Medicine, Kansai Med. Univ., Osaka, Japan)
Kazushi Tanimoto, Hiroaki Asai, Yuichi Ikeda, Toshiki Ochi, Kazuto Takeuchi, Jun Yamanouchi, Takaaki Hato, Katsuto Takenaka (The First Department of Internal Medicine, Ehime Univ., Ehime, Japan)
Yasuhito Terui1, Dai Maruyama2, Kazuhito Yamamoto3, Noriko Fukuhara4, Ilseung Choi5, Junya Kuroda6, Kiyoshi Ando7, Akira Hattori8, Kensei Tobinai2 (1.Cancer Inst. Hosp. JFCR, Tokyo, Japan, 2.Natl. Cancer Ctr. Hosp., Tokyo, Japan, 3.Aichi Cancer Ctr., Nagoya, Japan, 4.Tohoku Univ. Grad. Sch. Med., Sendai, Japan, 5.NHO Kyushu Cancer Ctr., Fukuoka, Japan, 6.Kyoto Pref. Univ. Med., Kyoto, Japan, 7.Tokai Univ., Isehara, Japan, 8.Ono Pharmaceutical Co., Ltd, Osaka, Japan)